Cite
Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways.
MLA
Shuhua Shen, et al. “Gypenosides Counteract Hepatic Steatosis and Intestinal Barrier Injury in Rats with Metabolic Associated Fatty Liver Disease by Modulating the Adenosine Monophosphate Activated Protein Kinase and Toll-like Receptor 4/Nuclear Factor Kappa B Pathways.” Pharmaceutical Biology, vol. 60, no. 1, Dec. 2022, pp. 1949–59. EBSCOhost, https://doi.org/10.1080/13880209.2022.2126503.
APA
Shuhua Shen, Kungen Wang, Yihui Zhi, & Yue Dong. (2022). Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways. Pharmaceutical Biology, 60(1), 1949–1959. https://doi.org/10.1080/13880209.2022.2126503
Chicago
Shuhua Shen, Kungen Wang, Yihui Zhi, and Yue Dong. 2022. “Gypenosides Counteract Hepatic Steatosis and Intestinal Barrier Injury in Rats with Metabolic Associated Fatty Liver Disease by Modulating the Adenosine Monophosphate Activated Protein Kinase and Toll-like Receptor 4/Nuclear Factor Kappa B Pathways.” Pharmaceutical Biology 60 (1): 1949–59. doi:10.1080/13880209.2022.2126503.